Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 67.7%

Neg 0% Neu 0% Pos 67.7%

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $28 to $30.